|Bid||0.00 x 1400|
|Ask||9.45 x 1000|
|Day's Range||5.91 - 6.10|
|52 Week Range||4.09 - 10.71|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Aspen Aerogels, Inc. (the "Company") (NYSE: ASPN) today announced that Don Young, Chief Executive Officer, and John Fairbanks, Chief Financial Officer, expect to discuss the Company's results for the second quarter ended June 30, 2020, during a conference call scheduled for Thursday, July 30, 2020, at 5:00 p.m. EDT. The Company also expects to release financial results for the second quarter on Thursday, July 30, 2020 following the market close.
After weeks of euphoric buying, volatility has made its way back to Wall Street. COVID-19 continues to take a heavy toll on the stock market, with a slew of new infections in the U.S. and China sending the stock market on a downward spiral. However, some stocks are holding up better than others. Small-caps have been charging forward, with the Russell 2000 outpacing the broader market since hitting a low point on March 23. Bearing this in mind, we used the TipRanks database to locate three small-cap companies that combine that positive niche position with a low cost of entry. These stocks will cost less than $8 per share to buy into, and offer potential growth of 40% or better. Ceco Environmental (CECE)We’ll start with Ceco, an industrial company focused on air purification systems. The company offers equipment and solutions for air scrubbing tech, dampers and diverters, industrial ventilation, and silencers to customers around the world. Ceco’s products are used in the oil and gas, power, battery manufacturing, and wastewater industries, among others.Ceco finished 2019 on a positive note, with $67.7 million in bookings and a backlog of $216.6 million. These numbers bode well for the company’s future, and have helped it to maintain profitability during the corona pandemic. In Q1, Ceco’s 15-cent EPS beat the forecast by 36% even as revenues missed expectations.Looking ahead, the company is expected to show continued growth in Q2, with revenue reaching as high as $86 million. The forecast for the full year 2020 is for over $358 million on the top line.Roth Capital analyst Gerry Sweeney sees CECE’s story as a simple one, about a company that does things right and is poised to benefit from that: “The COVID impact remains tough to gauge, but after several years of operational refinement, a solid balance sheet and mix of short, medium & long cycle businesses, CECE is prepared for the tide to recede.”To this end, Sweeney says "CECE looks attractive for a small cap industrial platform company." The analyst rates the stock a Buy along with a $9.00 price target, which implies a healthy 54% upside. (To watch Sweeney’s track record, click here)Overall, Wall Street agrees with Sweeney on Ceco. The company’s Strong Buy consensus rating based on a unanimous 5 Buys, all set in the past few weeks. The average price target of $9.20 suggests a premium of 56% from the current share price of $6.02. (See Ceco stock analysis on TipRanks)Aspen Aerogels (ASPN)Next up on our list is Aspen Aerogels, a leader in the industrial insulation market. Aspen’s products offer high-performance thermal insulation, flexible enough for uses across a range of industries. The company specializes in aerogel insulation, designing, developing, and manufacturing its full line of products. Aspen was hit hard by corona, as the economic shutdowns strangled the need for insulations. The share price lost over 50% in the initial market fall, and has not truly recovered. At the same time, with many states moving to reopen their economies, Aspen is preparing for a potential surge in demand. It’s important to note here that the company beat expectations in Q1 even as it lost 13 cents per share; forecast had been for a 23-cent loss. The Q2 outlook is a 20-cent loss; Aspen believes it can clear that bar, too.Craid-Hallum analyst Eric Stine writes that Aspen is well-positioned for the resumption of economic activity, with a solid balance sheet and pent-up demand offering the prospect of customers lined up through 2H20 into 2021. “While not surprising that it withdrew its 2020 guidance given the unprecedented level of uncertainty in the market, we continue to believe that ASPN’s value proposition and foundation remains strong and its core maintenance business resilient… Aspen Aerogels should see meaningful multi-year growth given a disruptive product offering with a compelling value proposition, blue-chip customer list, [and] low penetration (~4%) of the massive $3B energy insulation market,” Stine noted.Stine’s $12 price target is in line with his upbeat outlook, indicating an impressive potential for 65% growth in the coming year and fully supporting his Buy rating. (To watch Stine’s track record, click here)Once again, the Street’s aggregate view is also bullish. The unanimous analyst consensus of Strong Buy is based on 4 reviews, and the $10.25 average price target implies an upside of 41%. (See Aspen stock analysis on TipRanks)Kaleyra (KLR)Last but not least is Kaleyra, a cloud computing company that offers communications platforms and tools on the popular SaaS model. Products include SMS and voice calling, along with communications data insights and global contact numbers. In the second half of 2019, KLR’s earnings turned positive, but the COVID-19 epidemic brought that to a halt. The European operations are based in Milan, Italy – and northern Italy was particularly hard-hit by the virus. That outweighed the advantages of cloud-based communications systems in a telecommuting environment, and KLR reported a steep net loss in Q1. EPS came in at negative 35 cents.Kaleyra proved itself relevant in the crisis, however. The company made available a free texting service for Italy’s emergency medical services. The system allowed medical providers to keep in contact with each other and with potential patients while maintaining physical distance.For investors, however, probably the most important number here is 21%. That is the company’s year-over-year revenue growth. The top line reached $33.6 million in the first quarter, even with the epidemic. Northland’s 5-star analyst Michael Latimore covers KLR shares, and he was impressed enough by the company to assign a Buy rating. His $17 price target shows the extent of his confidence – it suggests a whopping 193% upside potential. (To watch Latimore’s track record, click here)In his comments, Latimore acknowledges that Kaleyra suffered disproportionately from COVID-19. Yet, the analyst went on to tick a list of pros: “Posted 21% growth despite CV19 issues in March. Has 0% customer churn among largest accounts, and 80% of revenue comes from customers that have been with KLR for over one year. Volumes improving in Italy over past few weeks. Ecommerce related services are up. Won new customers, such as the Red Cross.” This ticker, being new to the stock market, only has 3 analyst reviews on record – but all three agree that this is a stock to buy, making the analyst consensus a unanimous Strong Buy rating. Shares are priced at $5.75, and the average target of $12.83 implies an upside of 121%. (See Kaleyra's stock-price forecast on TipRanks)To find good ideas for small-cap stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 43.48% and -0.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen") today announced financial results for the first quarter of 2020, which ended March 31, 2020, and discussed recent business developments.
Aspen Aerogels, Inc. (the "Company") (NYSE: ASPN) today announced that Don Young, Chief Executive Officer, and John Fairbanks, Chief Financial Officer, expect to discuss the Company's results for the first quarter ended March 31, 2020, during a conference call scheduled for Thursday, April 30, 2020, at 5:00 p.m. EDT. The Company also expects to release financial results for the first quarter on Thursday, April 30, 2020 following the market close.
Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen") today announced financial results for the fourth quarter and full year 2019, which ended December 31, 2019, and discussed recent business developments.
Aspen Aerogels, Inc. (the "Company") (NYSE: ASPN) today announced that Don Young, Chief Executive Officer, and John Fairbanks, Chief Financial Officer, expect to discuss the Company's results for the fourth quarter ended December 31, 2019, during a conference call scheduled for Thursday, February 20, 2020, at 5:00 p.m. EST. As previously announced, the Company also expects to release financial results for the fourth quarter on Thursday, February 20, 2020, following the market close.
Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aspen also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering solely to cover over-allotments, if any. All of the securities in the proposed offering are to be sold by Aspen.
While 2019’s market performance broke records, Wall Street is less optimistic about 2020. The pros foresee those gains leveling off in coming months and a possible year-end cumulative increase of just 3% to 5%. Even though that would bring a profit to investors, it’s nothing to write home about.However, it’s important to remember two things: first, that is just a projection, and second, it’s based on the average upsides of an array of stocks. Which means, of course, that some stocks are going to have a much higher upside potential – and since there is no ceiling on that, it will still be possible to find investment opportunities with considerable upside.With this in mind, we’ve used the Stock Screener tool from TipRanks to sift through the 6,500 stocks in the platform’s database to find some of those likely winners. Each of the three stocks below has received at least one review from a top analyst suggesting an upside of 20% or more. Let’s dive in and look at the details.Aspen Aerogels, Inc. (ASPN)First on our list is a company in an unfamiliar niche. Aspen Aerogels manufactures and markets a variety of industrial insulation products. In this day of ever-increasing concern for environmental conservation, insulation technology will become more and more important – by nature, effective insulation increases the efficiency of any energy consuming process. Aspen’s products have applications in petrochemical refining, LNG storage, power generation, subsea offshore pipelines, as well as the building and construction sectors.The value of the company’s niche can be seen in the stock’s runup during 2019: ASPN shares gained a whopping 250% last year, starting on January 2 at $2.22 and finishing December 31 at $7.76. While the pace of gains has cooled since then, the stock is still up 7% in 2020.Looking ahead, the company has guided a net loss of 4 cents per share for Q4 2019. While in the red, this figure continues a sequential trend of declining quarterly losses. In Q3, ASPN beat the expectation of an 11-cent loss, reporting 9 cents. The company’s Q4 earnings release is scheduled for February 20.Chip Moore, 5-star analyst with Canaccord Genuity, sees plenty of strength in ASPN. In his comments on the stock, Moore writes, “Aspen Aerogels is a leading provider of high-performance aerogel-based insulation products to energy and industrial markets. The company’s proprietary technology offers better performance and total value versus traditional products. We continue to favor the long-term opportunity despite the challenging macro backdrop here.”To support his Buy rating, Moore increased the price target to $12, suggesting an upside potential of 45%. (To watch Moore’s track record, click here)ASPN shares hold a Strong Buy consensus rating, based on 4 Buy ratings and 1 Hold. Shares are selling for $8.27, a remarkably low cost of entry for a stock with such a high potential upside – the average price target of $12 matches Moore’s, given above. (See Aspen stock analysis on TipRanks) Alphabet, Inc. (GOOGL)Next up on our list needs no introduction. Alphabet is the parent holding company set up to own and operate Google, its main subsidiary. The corporate restructuring was completed in 2015. In trading since then, Alphabet has nearly tripled in value. In 2019, GOOGL shares gained 28%, matching the S&P 500 index and outperforming the Dow Jones by a wide margin.GOOGL pays no dividend, so investors’ gains are determined by share appreciation and corporate earnings. The company is expected to show an EPS of $12.76 for Q4 2019, to be reported on February 3. In three of the last four reported quarters, GOOGL has beaten the estimates. The company posted $136.8 billion in revenues for calendar year 2018, and is on track to exceed that figure for 2019.Aegis Capital analyst Victor Anthony, a 5-star analyst ranked 94 overall in the TipRanks database, sees GOOGL shares reaching $1,800 in the next 12 months. Appreciation to that level will translate to a gain of nearly 26% from current trading levels. (To watch Anthony’s track record, click here)Anthony published a research report on January 28 in which he reiterated his Buy rating on the stock, and said in his summary, “[W]e became more positive on Google's fundamentals across Search, YouTube, and Cloud, and see the shares outperforming the market this year, despite the regulatory risks, margin concerns, and competition for ad dollars. Our valuation reflects the increased estimates… due to our increased conviction in the continued strong growth of the core operating businesses.”With 27 recent ratings, including 24 Buys against just 3 Holds, GOOGL stock is a Strong Buy in the analyst consensus view. The fact that the consensus is more conservative than Anthony’s outlook is clear based on the average price target, which at $1,553.21 suggests an upside of just 8%. (See Alphabet stock-price forecast on TipRanks) Cytosorbents Corporation (CTSO)Last on our list is a biotech company, which should not come as a surprise as the space is well-known for boasting sky-high upside potentials. Cytosorbents develops blood purification technology based on porous polymer beads that remove harmful substances from the bloodstream. The technology has the potential to revolutionize the treatment of kidney disease, rendering current invasive dialysis procedures obsolete.Biotechs may be known for their high upside potential, but they’re also known for the hefty losses that companies frequently incur before achieving those upsides. The combination of huge overhead expenses and very long runup times before products are available for market cause the losses. Patient investors, however, endure them because the rewards are often impressive – when new drugs or medical technologies hit the markets, the combination of patient interest and patent royalties can bring massive returns.Even the expectation of a profitable medical breakthrough can boost shares. CTSO has gained 28% in January, just on early news reports of its blood cleansing technology. And that expectation can bring the love from Wall Street’s analysts.Writing from B. Riley FBR, Andrew D’Silva says, “We believe 4Q19 saw the initial benefits of CTSO substantially increasing its German sales force, as the company more than doubled the number of customer-facing sales reps it had in the region, while concomitantly increasing/establishing its presence in other direct sales regions. We anticipate CTSO will see a more significant benefit for new direct sales hires in 2020 as most additions were onboarded in 2H19. We believe the market opportunity for CTSO in Germany alone is immense. For example, CTSO generates well over $1 million in sales from one hospital in Germany.”D'Silva is quick to see the sales potential in Cytosorbents’ products, and gives the stock a Buy rating with a $12 price target. His target shows the extent of his confidence in this stock – it indicates room for a 143% share gain in the coming year. (To watch D’Silva’s track record, click here)CTSO has only 3 recent analyst reviews, but all are Buys, giving this stock a Strong Buy consensus rating. Shares sell for just $4.94, and the average price target of $11 implies an upside of 123%. (See Cytosorbents price targets and analyst ratings on TipRanks)
Consistent job growth, Fed's dovish stance along with government and infrastructural projects in domestic as well as international markets will reflect in the construction sector's Q4 results despite all odds.
Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen") today provided a business update, preliminary 2019 financial results and a 2020 financial outlook.
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 18.18% and 5.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?